Deciphera Pharmaceuticals Inc (DCPH)
25.48
+0.01
(+0.04%)
USD |
NASDAQ |
May 22, 16:00
25.48
0.00 (0.00%)
After-Hours: 20:00
Deciphera Pharmaceuticals Revenue (Quarterly): 45.00M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 45.00M |
| December 31, 2023 | 48.29M |
| September 30, 2023 | 43.31M |
| June 30, 2023 | 38.30M |
| March 31, 2023 | 33.44M |
| December 31, 2022 | 36.34M |
| September 30, 2022 | 35.97M |
| June 30, 2022 | 32.49M |
| March 31, 2022 | 29.22M |
| December 31, 2021 | 24.20M |
| Date | Value |
|---|---|
| September 30, 2021 | 23.22M |
| June 30, 2021 | 23.57M |
| March 31, 2021 | 25.16M |
| December 31, 2020 | 19.49M |
| September 30, 2020 | 15.45M |
| June 30, 2020 | 7.09M |
| March 31, 2020 | 0.062M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | 25.00M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.062M
Minimum
Mar 2020
48.29M
Maximum
Dec 2023
28.09M
Average
27.19M
Median
Revenue (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 11.86B |
| Dynavax Technologies Corp | 50.79M |
| Gilead Sciences Inc | 6.686B |
| Esperion Therapeutics Inc | 137.74M |
| SINTX Technologies Inc | 0.309M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -45.08M |
| Total Expenses (Quarterly) | 93.85M |
| EPS Diluted (Quarterly) | -0.52 |
| Enterprise Value | 1.930B |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | -100.2% |
| Earnings Yield | -8.67% |
| Normalized Earnings Yield | -8.673 |